Ash 2018 – Sobi still has a mountain to climb with Gamifant
Launch could be trickier than approval, not least because of problems diagnosing patients with primary haemophagocytic lymphohistiocytosis.
Ash 2018 preview – smaller groups get their turn in the spotlight
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Pre-Esmo jitters for Roche
Discontinuations and an unusual revelation about Tecentriq’s breast cancer data dominated the R&D part of the company’s third-quarter results call.
“Don’t eat me” competition finds Celgene discontinuation hard to digest
Celgene’s surprise termination of a clinical trial makes for a day of soul-searching among other followers of the anti-CD47 approach.
Looking beyond factors in haemophilia
Next-generation projects, including gene therapies, could soon be shaking up the haemophilia market.
Does Roche have the haemophilia X factor?
Experts expect Roche's Hemlibra to dominate the inhibitor patient population, but to be a big deal it will need to impress in non-inhibitor patients, too.
